What’s the current market cap for Aeglea BioTherapeutics, Inc. stock?

Aeglea BioTherapeutics, Inc. (SYRE) has a market cap of $7.2bn as of June 17, 2026.

What is the P/E ratio for Aeglea BioTherapeutics, Inc. stock?

The price to earnings (P/E) ratio for Aeglea BioTherapeutics, Inc. (SYRE) stock is 0 as of June 17, 2026.

Does Aeglea BioTherapeutics, Inc. stock pay dividends?

No, Aeglea BioTherapeutics, Inc. (SYRE) stock does not pay dividends to its shareholders as of June 17, 2026.

When is the next Aeglea BioTherapeutics, Inc. dividend payment date?

Aeglea BioTherapeutics, Inc. (SYRE) stock does not pay dividends to its shareholders.

What is the beta indicator for Aeglea BioTherapeutics, Inc.?

Aeglea BioTherapeutics, Inc. (SYRE) has a beta rating of 3.13. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Aeglea BioTherapeutics, Inc. stock | $SYRE Share Price

13:30

15:10

16:45

18:25

20:00

About Aeglea BioTherapeutics, Inc.

Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Ticker

$SYRE

Sector

Health

Primary listing

NASDAQ

Employees

112

Headquarters

Waltham, United States

Website

www.spyre.com

SYRE Metrics

BasicAdvanced

$7.2bn

-$2.17

3.13

Bulls say / Bears say

Favorable interim Phase 1 results for SPY003 showed a strong safety profile and an approximately 85-day half-life, supporting the potential for quarterly or twice-yearly maintenance dosing (Nasdaq).

Diversified pipeline: all four investigational antibodies (SPY001, SPY002, SPY072, SPY003) reported positive Phase 1 data and have progressed into Phase 2 trials, with up to six proof-of-concept readouts expected in 2026 (Nasdaq).

Strong balance sheet: $783 million pro forma cash as of September 30, 2025, provides funding through the second half of 2028, supporting clinical development through key value milestones (Nasdaq).

High cash burn: in the third quarter of 2025, net cash used in operating activities was $37.1 million and R&D expenses totaled $45.2 million, highlighting heavy ongoing clinical spending that could strain the cash runway if costs increase (Nasdaq).

Intense competition in the IL-23 market: AbbVie's Skyrizi generated $4.48 billion in Q1 2026 sales, underscoring the strength of major incumbents that SPY003 will have to compete against to capture market share (Reuters).

Reliance on capital markets: raising $316 million in gross proceeds from the October 2025 underwritten public offering demonstrates ongoing funding needs and increases the risk of future equity dilution as Phase 2 data readouts approach (Nasdaq).

Data summarised monthly by Lightyear AI. Last updated on 22 May 2026.

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $SYRE

Capital at risk

Market closed

Upcoming events

No upcoming events

Bulls say / Bears say

Favorable interim Phase 1 results for SPY003 showed a strong safety profile and an approximately 85-day half-life, supporting the potential for quarterly or twice-yearly maintenance dosing (Nasdaq).

Strong balance sheet: $783 million pro forma cash as of September 30, 2025, provides funding through the second half of 2028, supporting clinical development through key value milestones (Nasdaq).

Data summarised monthly by Lightyear AI. Last updated on 22 May 2026.